Group therapy for mood disorders: A meta-analysis

Objective: The aim of this study was to perform a quantitative analysis to evaluate the efficacy of cognitive behavioral therapy (CBT) on mood disorders, sleep, fatigue, and its impact on quality of life (QOL) in Parkinson's Disease (PD).Methods: We searched for randomized controlled trials in three electronic databases. Fourteen studies, including 507 patients with PD, met the inclusion criteria. We determined the pooled efficacy by standard mean differences and 95% confidence intervals, using I2 to reveal heterogeneity.Results: The result showed CBT had a significant effect on depression [−0.93 (95%CI, −1.19 to −0.67, P < 0.001)] and anxiety [−0.76 (95%CI, −0.97 to −0.55, P < 0.001)]. Moderate effect sizes were noted with sleep disorders [−0.45 (95% CI, −0.70 to −0.20, P = 0.0004)]. There was no evident impact of CBT on fatigue or QOL. We found an intervention period >8 weeks was advantageous compared with <8 weeks, and CBT implemented in non-group was more effective than in group. Between the delivery methods, no significant difference was found.Conclusion: We found that CBT in patients with PD was an efficacious therapy for some non-motor symptoms in PD, but not efficacious for fatigue and QOL. These results suggest that CBT results in significant improvement in PD and should be used as a conventional clinical intervention.

Download Full-text

TheCLOCKGene and Mood Disorders: A Case-Control Study and Meta-analysis

Chronobiology International ◽

10.3109/07420528.2011.609951 ◽

2011 ◽

Vol 28 (9) ◽

pp. 825-833 ◽

Cited By ~ 28

Author(s):

Taro Kishi ◽

Reiji Yoshimura ◽

Yasuhisa Fukuo ◽

Tsuyoshi Kitajima ◽

Tomo Okochi ◽

...

Keyword(s):

Mood Disorders ◽

Case Control Study ◽

Meta Analysis ◽

Case Control ◽

Control Study

Download Full-text

Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis

Australian & New Zealand Journal of Psychiatry ◽

10.1177/00048674211054740 ◽

2021 ◽

pp. 000486742110547

Author(s):

Sukanta Saha ◽

Carmen CW Lim ◽

Louisa Degenhardt ◽

Danielle L Cannon ◽

Monique Bremner ◽

...

Keyword(s):

Mood Disorders ◽

Drug Dependence ◽

Odds Ratio ◽

Meta Analysis ◽

Geographical Location ◽

Dysthymic Disorder ◽

Increased Risk ◽

Meta Analyses ◽

Substance Related Disorders ◽

Study Designs

Background and Objectives: Evidence indicates that mood disorders often co-occur with substance-related disorders. However, pooling comorbidity estimates can be challenging due to heterogeneity in diagnostic criteria and in the overall study design. The aim of this study was to systematically review and, where appropriate, meta-analyse estimates related to the pairwise comorbidity between mood disorders and substance-related disorders, after sorting these estimates by various study designs. Methods: We searched PubMed (MEDLINE), Embase, CINAHL and Web of Science for publications between 1980 and 2017 regardless of geographical location and language. We meta-analysed estimates from original articles in 4 broadly defined mood and 35 substance-related disorders. Results: After multiple eligibility steps, we included 120 studies for quantitative analysis. In general, regardless of variations in diagnosis type, temporal order or use of adjustments, there was substantial comorbidity between mood and substance-related disorders. We found a sixfold elevated risk between broadly defined mood disorder and drug dependence (odds ratio = 5.7) and fivefold risk between depression and cannabis dependence (odds ratio = 4.9) while the highest pooled estimate, based on period prevalence risk, was found between broadly defined dysthymic disorder and drug dependence (odds ratio = 11.3). Based on 56 separate meta-analyses, all pooled odds ratios were above 1, and 46 were significantly greater than 1 (i.e. the 95% confidence intervals did not include 1). Conclusion: This review found robust and consistent evidence of an increased risk of comorbidity between many combinations of mood and substance-related disorders. We also identified a number of under-researched mood and substance-related disorders, suitable for future scrutiny. This review reinforces the need for clinicians to remain vigilant in order to promptly identify and treat these common types of comorbidity.

Download Full-text

Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis

Psychoneuroendocrinology ◽

10.1016/j.psyneuen.2019.104420 ◽

2019 ◽

Vol 110 ◽

pp. 104420 ◽

Cited By ~ 5

Author(s):

Giulia Lombardo ◽

Daniela Enache ◽

Laura Gianotti ◽

Alan F. Schatzberg ◽

Allan H. Young ◽

...

Keyword(s):

Mood Disorders ◽

Meta Analysis ◽

Baseline Cortisol

Download Full-text

Magnesium and mood disorders: systematic review and meta-analysis

BJPsych Open ◽

10.1192/bjo.2018.22 ◽

2018 ◽

Vol 4 (4) ◽

pp. 167-179 ◽

Cited By ~ 12

Author(s):

Danny Phelan ◽

Patricio Molero ◽

Miguel A. Martínez-González ◽

Marc Molendijk

Keyword(s):

Systematic Review ◽

Mood Disorders ◽

Symptom Severity ◽

Odds Ratio ◽

Potential Role ◽

Meta Analysis ◽

Blood Levels ◽

Cross Sectional ◽

Bodily Fluids ◽

Meta Analyses

BackgroundMagnesium (Mg2+) has received considerable attention with regards to its potential role in the pathophysiology of the mood disorders, but the available evidence seems inconclusive.AimsTo review and quantitatively summarise the human literature on Mg2+intake and Mg2+blood levels in the mood disorders and the effects of Mg2+supplements on mood.MethodSystematic review and meta-analyses.ResultsAdherence to a Mg2+-rich diet was negatively associated with depression in cross-sectional (odds ratio = 0.66) but not in prospective studies. Mg2+levels in bodily fluids were on average higher in patients with a mood disorder (Hedge'sg = 0.19), but only in patients treated with antidepressants and/or mood stabilisers. There was no evident association between Mg2+levels and symptom severity. Mg2+supplementation was associated with a decline in depressive symptoms in uncontrolled (g = −1.60) but not in placebo-controlled trials (g = −0.21).ConclusionOur results provide little evidence for the involvement of Mg2+in the mood disorders.Declaration of interestNone.

Download Full-text